AngioDynamics (ANGO) Misses Q1 EPS by 4c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance
October 6, 2022 7:00 AM EDTFiscal Year 2023 First Quarter Highlights
Net sales of $81.5 million increased 5.9% compared to the prior-year quarter Med Tech net sales of $22.8 million increased 29.6% Med Device net sales of $58.7 million decreased 1.1% Gross margin of 51.9% declined 20 basis points year over year GAAP loss per share of $0.33 and adjusted loss per share of $0.06 The Company commenced the Full Market Release of the AlphaVac F18 Mechanical Thrombectomy deviceLATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ:... More
